Baird Reiterates Bullish View on Sarepta (SRPT) as ESSENCE Starts Dosing
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Baird analyst Brian Skorney reiterated an Outperform rating and $102 PT on Sarepta Therapeutic (NASDAQ: SRPT) after the company announced that dosing has started in the Phase 3 ESSENCE study of SRP-4045 and SRP-4053.
Skorney commented, "The one-of-a-kind study is testing two separate exon-skipping agents with the same backbone as eteplirsen in exon 45/53 amenable patients, which comprise about another 16% of DMD patients. ESSENCE, a placebo-controlled, 96-week study, also has potential to be confirmatory of the benefit provided by eteplirsen. If the trial is successful, it could mean more than doubling of Sarepta’s addressable population in the next few years."
Shares of Sarepta Therapeutic closed at $62.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) Target of Cautious Article
- Oppenheimer Raises Price Target on Microsoft (MSFT) to $65 Following 1Q Beat
- UPDATE: Stifel Downgrades SL Green Realty (SLG) to Hold
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Related EntitiesRobert W Baird
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!